Remove Clinical Development Remove Presentation Remove Protein Expression
article thumbnail

Roche to present new data in multiple sclerosis and neuromyelitis optica spectrum disorder at MSVirtual2020

The Pharma Data

Other data to be presented will show high treatment persistence and strong adherence for patients treated with OCREVUS compared to other DMTs in real-world settings. A full list of Roche presentations can be found at: [link]. Presentations at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting include: Medicine. Abstract Title.

article thumbnail

2021 AAN highlight impact and breadth of expanding neuroscience portfolio

The Pharma Data

Additional presentations on investigational programmes, including Alzheimer’s disease and Huntington’s disease, help advance scientific understanding of neurological disorders. Roche will present data from five studies from the EVRYSDI clinical development programme, which was designed to represent a broad spectrum of people living with SMA.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

VALNEVA AND PFIZER ANNOUNCE INITIATION OF PHASE 2 STUDY FOR LYME DISEASE VACCINE CANDIDATE

The Pharma Data

VLA15 is the only active Lyme disease vaccine candidate in clinical development today, and covers six serotypes that are prevalent in North America and Europe. This investigational multivalent protein subunit vaccine targets the outer surface protein A (OspA) of Borrelia, an established mechanism of action for a Lyme disease vaccine.

Vaccine 52
article thumbnail

Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate

The Pharma Data

Valneva and Pfizer plan to submit these data for publication and presentation at a future scientific congress. About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.

Vaccine 52
article thumbnail

Datopotamab Deruxtecan Combinations Showed Encouraging TumorResponses in Patients with Advanced Non-Small Cell Lung Cancer inTROPION-Lung02 Phase 1b trial

The Pharma Data

Results will be presented on June 6 during an oral presentation (#9004) at the American Society of Clinical Oncology Annual Meeting (#ASCO23). 3,4,5 TROP2 is a protein expressed in more than 90% of NSCLC tumors. More than one million people are diagnosed with NSCLC at an advanced stage each year.

Trials 40
article thumbnail

Rapid delivery of toxicological material

Drug Target Review

Drug developer companies across the pharma industry report notable reductions in drug development timelines where 10 to 12 months, from lead monoclonal antibody (mAb) identification to IND application, is the new norm and in which earlier Tox material generation has been a critical component for shortening IND timelines.

article thumbnail

Five Promising Treatment Areas in Early-Phase Drug Development in 2024

Alta Sciences

They work by binding to specific sequences of nucleotides present within the mRNA structure and can induce mechanisms that either decrease, restore, or modify protein expression. And since proteins are often linked to disease, there's huge potential to treat a broad range of diseases with this technology.